Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer

Recruiting now

Conditions studied: Ovarian Cancer

In brief

Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage. Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.

Key facts

Study ID

NCT06907771

Run by

University Hospital, Strasbourg, France

People needed

130

Starts

2024-04-22

Expected to finish

2025-12-22

Last updated by the study team

2025-04-02

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Adult patient (≥18 years old)
• Operated on at the HUS between January 1, 2010 and December 31, 2022
• Having undergone primary or interval cytoreductive surgery
• Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin

You may not qualify if…

• Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques.
• Autres types histologiques de cancer de l'ovaire
• Stades de la maladie FIGO I, II, IIIA et IIIC
• Chirurgie de clôture.

Where it is running

• Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.